Map of COVID-19 and human protein interactions reveals drug targets
Researchers have identified which SARS-CoV-2 proteins physically associate with proteins in human cells, revealing potential drug targets to treat the COVID-19 coronavirus.
List view / Grid view
Researchers have identified which SARS-CoV-2 proteins physically associate with proteins in human cells, revealing potential drug targets to treat the COVID-19 coronavirus.
A researcher has revealed that angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARBs) may increase the risk of severe lung complications in COVID-19.
In this in-depth focus are features on the best data management options currently available and how the future of drug discovery will be connected and fully automated.
The articles in this in-depth focus explain how informatics aids in the development of genomic research and outline the next steps for AI to progress in pharma.
Researchers have shown that natural killer (NK) cells work best as an immunotherapy when in an early stage of development, so could be manufactured from pluripotent stem cells.
This In-Depth Focus includes articles on antibodies as a treatment for COVID-19, the importance of understanding every aspect of an ADC and the potential of antibodies as a targeted cancer therapeutic.
Included in this In-Depth Focus are articles on why human tissue models are best for testing nephrotoxicity and how genetic and pharmacogenomic testing can improve healthcare options.
Drug Target Review has created a COVID-19 research hub with forum space for discussions and a place to share your research - plus all of our articles and news.
Researchers have revealed a new substance that can bind well to serotonin transporters, offering a potential way to lessen the side effects of antidepressant therapies.
A team of Russian scientists has suggested a new method to measure the sizes of atoms as well as their intermolecular interactions, which they say could help drug design.
This issue includes a spotlight on how genomic assays could revolutionise healthcare, a discussion on how lab automation can improve drug discovery and an analysis of whether antibodies can provide an effective coronavirus treatment. Other article topics in this issue include immuno-oncology and artificial intelligence.
Using the ubiquitin-proteasome system to fight inflammatory conditions could provide more treatment options for patients. Dr Jared Gollob from Kymera Therapeutics explains why targeted protein degradation is the way forward for autoinflammatory and autoimmune disease therapies.
Using X-ray crystallography, researchers have revealed the structure of the SARS-CoV-2 main protease, designing an inhibitor to bind to this target and prevent viral replication.
A statement from scientists has highlighted that improving the understanding of COVID-19 infections in children will help researchers to develop better treatments.
Researchers have shown that incorporating noncanonical amino acids (ncAAs) in phage display expands the range of peptides it can identify.